SLC13A5-IN-1

Overview

SLC13A5-IN-1 is a selective sodium-citrate co-transporter ( SLC13A5 ) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14 C-citrate with an IC 50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Sodium Channel

Product Information

• Catalog No.: HY-125990
• CAS No.: 2227548-95-8
• Molecular Formula: C19H19Cl3N2O3S
• Molecular Weight: 461.79
• Purity: 98.62%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source